Stocks
News
ETFs
Economy
Currencies
Press Releases
Legend Biotech Corporation - American Depositary Shares (LEGN)
Last Price
37.64
Change
+2.86 (8.22%)
NASDAQ
· Last Trade: Jun 11th, 12:06 AM EDT
Quote
News
Press Releases
Chart
Historical
FAQ
About
Competitors
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday
benzinga.com
Via
Benzinga
· June 10, 2025
Quanex Building Products, Manchester United, Byrna Technologies And Other Big Stocks Moving Higher On Friday
benzinga.com
Via
Benzinga
· June 6, 2025
What Does the Market Think About Legend Biotech?
benzinga.com
Via
Benzinga
· April 29, 2025
Netflix, Ericsson, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Monday
benzinga.com
Via
Benzinga
· April 15, 2025
Is Legend Biotech Gaining or Losing Market Support?
benzinga.com
Via
Benzinga
· March 5, 2025
Peering Into Legend Biotech's Recent Short Interest
benzinga.com
Via
Benzinga
· February 17, 2025
Earnings Scheduled For May 13, 2025
benzinga.com
Via
Benzinga
· May 13, 2025
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
benzinga.com
Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.
Via
Benzinga
· April 8, 2025
5 Analysts Have This To Say About Legend Biotech
benzinga.com
Via
Benzinga
· April 8, 2025
What Does the Market Think About Legend Biotech?
benzinga.com
Via
Benzinga
· April 3, 2025
Demystifying Legend Biotech: Insights From 5 Analyst Reviews
benzinga.com
Via
Benzinga
· March 17, 2025
Where Legend Biotech Stands With Analysts
benzinga.com
Via
Benzinga
· January 23, 2025
Breaking Down Legend Biotech: 9 Analysts Share Their Views
benzinga.com
Via
Benzinga
· December 30, 2024
(LEGN) - Analyzing Legend Biotech's Short Interest
benzinga.com
Via
Benzinga
· December 16, 2024
Deep Dive Into Legend Biotech Stock: Analyst Perspectives (10 Ratings)
benzinga.com
Via
Benzinga
· December 10, 2024
Earnings Scheduled For November 12, 2024
benzinga.com
Via
Benzinga
· November 12, 2024
9 Analysts Have This To Say About Legend Biotech
benzinga.com
Via
Benzinga
· October 16, 2024
Earnings Scheduled For March 11, 2025
benzinga.com
Via
Benzinga
· March 11, 2025
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
benzinga.com
Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly extends survival in multiple myeloma patients, reducing the risk of death by 45% compared to standard therapies.
Via
Benzinga
· September 30, 2024
Where Legend Biotech Stands With Analysts
benzinga.com
Via
Benzinga
· September 27, 2024
Peering Into Legend Biotech's Recent Short Interest
benzinga.com
Via
Benzinga
· September 6, 2024
Beyond The Numbers: 14 Analysts Discuss Legend Biotech Stock
benzinga.com
Via
Benzinga
· August 28, 2024
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma
investors.com
Legend Biotech said its J&J-partnered CAR-T drug cut the risk of death by 45% over standard treatment for multiple myeloma.
Via
Investor's Business Daily
· September 27, 2024
Looking Into Legend Biotech's Recent Short Interest
benzinga.com
Via
Benzinga
· August 16, 2024
Beyond The Numbers: 15 Analysts Discuss Legend Biotech Stock
benzinga.com
Via
Benzinga
· August 12, 2024
